ERBB2 and neoplasm: However, it has been shown in previous studies that 227Th conjugated to trastuzumab could specifically kill HER2-overexpressing cancer cells in vitro and had a therapeutic effect on HER2-overexpressing subcutaneous tumor xenografts [11], [12], [13].